Denali Therapeutics (DNLI) Cash from Investing Activities (2017 - 2026)

Denali Therapeutics (DNLI) has 10 years of Cash from Investing Activities data on file, last reported at $94.5 million in Q1 2026.

• On a quarterly basis, Cash from Investing Activities rose 403.84% year-over-year to $94.5 million in Q1 2026; TTM through Mar 2026 was $331.0 million, a 13.62% decrease from a year earlier, with the FY2025 full-year figure at $255.3 million, up 387.62% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at $94.5 million, up from $20.8 million in the prior quarter.
• Over the last five years, Cash from Investing Activities for DNLI reached as high as $172.2 million in Q4 2024 and fell as low as -$453.2 million in Q1 2024.
• Historically, Cash from Investing Activities has averaged $21.7 million across 5 years, with a median of $73.0 million in 2023.
• Across the five-year window, Cash from Investing Activities soared 554.45% in 2023 and tumbled 388.8% in 2024, its largest moves.
• Year by year, Cash from Investing Activities stood at -$127.6 million in 2022, then jumped by 157.27% to $73.0 million in 2023, then surged by 135.75% to $172.2 million in 2024, then tumbled by 87.94% to $20.8 million in 2025, then soared by 354.83% to $94.5 million in 2026.
• Per Business Quant data, the three most recent Cash from Investing Activities figures were $94.5 million in Q1 2026, $20.8 million in Q4 2025, and $57.8 million in Q3 2025.